A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis

Bibliography

• Ruscetti FW, Morgan DA, Gallo RC. Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol 1977;119:131-8
   PubMed Web of Science ®Google Scholar
• Mizel SB, Farrar JJ. Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors. Cell Immunol 1979;48:433-6
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Kozak RW, Tsudo M, et al. IL-2 receptors in adult T-cell leukemia: a target for immunotherapy. Hamatol Bluttransfus 1987;31:110-15
   Google Scholar
• Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013;10(1):55-67
   PubMed Web of Science ®Google Scholar
• Deiß A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013;13(3):313-35
   PubMed Web of Science ®Google Scholar
• Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care 2013;19(2 Suppl):S21-7
   PubMed Web of Science ®Google Scholar
• Waldmann TA, O’Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998;10:507-12
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22(3):329-41
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R-alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-6
   PubMed Web of Science ®Google Scholar
• Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009;66:471-9
   PubMed Web of Science ®Google Scholar
• Baan CC, Balk AH, van Riemsdijk IC, et al. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation 2003;75:1704-10
   PubMed Web of Science ®Google Scholar
• Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011;17:604-9
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta. Proc Natl Acad Sci USA 2004;101:8705-8
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40
   PubMed Web of Science ®Google Scholar
• Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-9
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Herman ML, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011;77:1877-86
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-8
   PubMed Web of Science ®Google Scholar
• Elkins J, Sheridan J, Amaravadi L, et al. CD56bright natural killer cell expansion predicts response to daclizumab HYP treatment in RRMS: results of the SELECT trial (S31.004). Neurology 2012;78(Meeting Abstracts 1):S31.004
   Google Scholar
• Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet 2014;53(10):907-18
   PubMed Web of Science ®Google Scholar
• Waldmann T, Longo D, Leonard W, et al. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res 1985;45(9 Suppl):4559s-62s
   PubMed Web of Science ®Google Scholar
• Lehkey T, Levin M, Kubota R, et al. Reduction in HTLV-1 proviral load and spontaneous lymphoproliferation in HTLV-1-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998;44:942-7
   PubMed Web of Science ®Google Scholar
• Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-7
   PubMed Web of Science ®Google Scholar
• Rose J, Burns J, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-9
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9:381-90
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol 2014;13(5):472-81
   PubMed Web of Science ®Google Scholar
• Mehta M, Amaravadi L, Gold R, et al. Reversal of the pharmacodynamic effects of daclizumab HYP following treatment washout: results from the SELECTION study [abstract P05:188]. In: 65th Annual Meeting of the American Academy of Neurology; 16 – 23 March 2013; San Diego, CA
   Google Scholar
• Gorman M, Tillema J, Ciliax A, et al. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 2012;69:78-81
   PubMed Web of Science ®Google Scholar
• Borges I, Shea C, Ohayon J, et al. The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2013;2:133-40
   PubMedGoogle Scholar
• Alì E, Healy B, Stazzone L, et al. Daclizumab in treatment of multiple sclerosis patients. Mult Scler 2009;15:272-4
   PubMed Web of Science ®Google Scholar
• Milo R. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2014;7(1):7-21
   PubMed Web of Science ®Google Scholar
• Selmaj K, Kappos L, Arnold DL, et al. Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study. ACTRIMS-ECTRIMS; 09 November 2014; 2014
   Google Scholar
• Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology 2014;82(11):984-8
   PubMed Web of Science ®Google Scholar
• Webster A, Playford E, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004;77:166-76
   PubMed Web of Science ®Google Scholar
• Elkins J, Sheridan J, Amaravadi L, et al. CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2015;2(2):e65
   PubMed Web of Science ®Google Scholar
• Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 2005;19:705-10
   PubMed Web of Science ®Google Scholar
• Fox R, Miller D, Phillips J, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• O‘Connor P, Wolinsky J, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014;261(4):773-83
   PubMed Web of Science ®Google Scholar
• Cohen J, Coles A, Arnold D, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles A, Twyman C, Arnold D, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87
   PubMed Web of Science ®Google Scholar